BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D™ Fusion Imaging for Interventional Cardiology
Partnership Announcement: BioCardia and CART-Tech have entered an exclusive agreement to develop and commercialize Heart3D™ Fusion Imaging, a system designed to enhance cardiac imaging by fusing 2D x-ray images with 3D anatomical models for improved biotherapeutic interventions and biopsies.
Market Potential: The partnership aims to leverage their combined expertise in cardiac procedures, with estimates suggesting that a single approved biologic therapy could generate significant annual revenue, enhancing procedural experiences for cardiologists and benefiting patients with cardiovascular diseases.
Trade with 70% Backtested Accuracy
Analyst Views on BCDA
No data
About BCDA
About the author
BioCardia Completes FDA Pre-Submission for Helix Catheter Approval
- FDA Pre-Submission Completed: BioCardia has completed its FDA pre-submission for the Helix transendocardial delivery catheter, supported by data from 15 clinical trials demonstrating safety and efficacy in cardiac therapies, which is expected to enhance the company's market position in cardiovascular disease treatment.
- Breakthrough Designation: The pre-submission is conducted under the FDA Breakthrough Designation for the CardiAMP Cell Therapy System, with BioCardia planning to align with the FDA on the regulatory pathway within the next 45 days, potentially accelerating market entry.
- Significant Technical Advantages: The Helix catheter has demonstrated a three-fold increase in effective dosing compared to open surgical access and superior procedural safety in clinical trials, which is likely to attract more biopharmaceutical partners to utilize its innovative technology.
- Huge Market Potential: FDA approval will reduce development risks for BioCardia's therapies for heart failure and chronic myocardial ischemia, paving the way for future approvals of its autologous and allogeneic cell therapies to meet enormous unmet medical needs.
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%
- Strategic Alternatives: IO Biotech announced it will explore various strategic alternatives to maximize shareholder value, resulting in a 19.36% stock surge to $0.25, indicating strong investor interest in potential mergers or asset sales.
- Cost-Cutting Measures: The company is evaluating further reductions in force and other measures to significantly cut operating expenses, aiming to enhance financial flexibility and pave the way for future strategic options.
- Speculative Trading: Cue Biopharma's stock rose 10.67% to $0.42 despite no new company news, suggesting speculative trading activity may reflect investor optimism in the biotech sector.
- Continued Growth Trend: InfuSystem and Cabaletta Bio saw stock increases of 7.19% and 7.68%, respectively, demonstrating ongoing investor interest in the medical services and biotech sectors, despite the absence of new corporate updates.
BioCardia Completes Third Clinical Consultation with Japan's PMDA for CardiAMP Therapy
- Clinical Consultation Progress: BioCardia has completed its third preliminary clinical consultation with Japan's PMDA, preparing for formal discussions on the CardiAMP therapy for heart failure, which could pave the way for new treatment options in the Japanese market.
- Efficacy Data Support: Data from three clinical trials indicate that CardiAMP therapy shows positive outcomes in improving survival rates and reducing major adverse cardiovascular events, highlighting its potential value in treating heart failure patients.
- Innovative Treatment Mechanism: The CardiAMP cell therapy utilizes the patient's own bone marrow cells delivered via a minimally invasive catheter procedure to repair microvascular dysfunction, offering a new therapeutic option for ischemic heart failure patients.
- Clear Regulatory Pathway: The PMDA has indicated that BioCardia can advance to formal clinical consultation, and if the data sufficiently supports safety and efficacy, it will facilitate the company's application for regulatory approval in Japan, further driving its expansion in the Asia-Pacific market.
BioCardia Elects Marvin Slosman to Board of Directors
- New Board Appointment: BioCardia announced the election of Marvin Slosman to its Board of Directors effective December 2, 2025, bringing deep expertise in interventional cardiology that is expected to drive innovation and market expansion in cardiovascular disease treatment.
- Rich Leadership Experience: Slosman, who previously served as CEO of InspireMD and held senior commercial leadership roles at Johnson & Johnson, GE Healthcare, and Baxter International, brings extensive market development and product commercialization experience that will aid BioCardia's strategic growth.
- Gratitude to Former Director: BioCardia expressed appreciation for departing board member Richard Krasno, who provided guidance during key milestones, particularly in the FDA approval of the CardiAMP cell therapy and the Morph DNA product.
- Strategic Company Development: The appointment of Slosman is expected to significantly support BioCardia's clinical value creation and global market expansion, further advancing the company's innovative solutions for treating cardiovascular and pulmonary diseases.
BioCardia Enhances Leadership Team by Appointing Farhan Shahab as Vice President of Quality
New Appointment: BioCardia, Inc. has appointed Farhan Shahab as Vice President of Quality, bringing over 25 years of experience in quality management and regulatory affairs from various companies in the healthcare sector.
Previous Experience: Shahab's prior roles include Vice President of Quality and Regulatory at Welldoc, Senior Director at Intuity Medical, and Director at Moximed, showcasing a strong background in product quality management across multiple medical device categories.
CEO's Statement: Peter Altman, CEO of BioCardia, expressed confidence in Shahab's expertise, stating that his leadership and experience will enhance the company's ability to commercialize investigational products.
Company Overview: BioCardia specializes in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with ongoing development of clinical-stage product candidates and innovative biotherapeutic delivery platforms.
BioCardia, Inc. Reports Smaller Q3 Loss, Surpassing Expectations
Earnings Performance: BioCardia, Inc. reported a loss of $1.48 million for the third quarter, an improvement from a loss of $1.74 million in the same period last year.
Earnings Per Share: The company's earnings per share (EPS) were -$0.24, compared to -$0.61 in the previous year, beating analysts' expectations of -$0.25 per share.
BioCardia Completes FDA Pre-Submission for Helix Catheter Approval
- FDA Pre-Submission Completed: BioCardia has completed its FDA pre-submission for the Helix transendocardial delivery catheter, supported by data from 15 clinical trials demonstrating safety and efficacy in cardiac therapies, which is expected to enhance the company's market position in cardiovascular disease treatment.
- Breakthrough Designation: The pre-submission is conducted under the FDA Breakthrough Designation for the CardiAMP Cell Therapy System, with BioCardia planning to align with the FDA on the regulatory pathway within the next 45 days, potentially accelerating market entry.
- Significant Technical Advantages: The Helix catheter has demonstrated a three-fold increase in effective dosing compared to open surgical access and superior procedural safety in clinical trials, which is likely to attract more biopharmaceutical partners to utilize its innovative technology.
- Huge Market Potential: FDA approval will reduce development risks for BioCardia's therapies for heart failure and chronic myocardial ischemia, paving the way for future approvals of its autologous and allogeneic cell therapies to meet enormous unmet medical needs.
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%
- Strategic Alternatives: IO Biotech announced it will explore various strategic alternatives to maximize shareholder value, resulting in a 19.36% stock surge to $0.25, indicating strong investor interest in potential mergers or asset sales.
- Cost-Cutting Measures: The company is evaluating further reductions in force and other measures to significantly cut operating expenses, aiming to enhance financial flexibility and pave the way for future strategic options.
- Speculative Trading: Cue Biopharma's stock rose 10.67% to $0.42 despite no new company news, suggesting speculative trading activity may reflect investor optimism in the biotech sector.
- Continued Growth Trend: InfuSystem and Cabaletta Bio saw stock increases of 7.19% and 7.68%, respectively, demonstrating ongoing investor interest in the medical services and biotech sectors, despite the absence of new corporate updates.
BioCardia Completes Third Clinical Consultation with Japan's PMDA for CardiAMP Therapy
- Clinical Consultation Progress: BioCardia has completed its third preliminary clinical consultation with Japan's PMDA, preparing for formal discussions on the CardiAMP therapy for heart failure, which could pave the way for new treatment options in the Japanese market.
- Efficacy Data Support: Data from three clinical trials indicate that CardiAMP therapy shows positive outcomes in improving survival rates and reducing major adverse cardiovascular events, highlighting its potential value in treating heart failure patients.
- Innovative Treatment Mechanism: The CardiAMP cell therapy utilizes the patient's own bone marrow cells delivered via a minimally invasive catheter procedure to repair microvascular dysfunction, offering a new therapeutic option for ischemic heart failure patients.
- Clear Regulatory Pathway: The PMDA has indicated that BioCardia can advance to formal clinical consultation, and if the data sufficiently supports safety and efficacy, it will facilitate the company's application for regulatory approval in Japan, further driving its expansion in the Asia-Pacific market.
BioCardia Elects Marvin Slosman to Board of Directors
- New Board Appointment: BioCardia announced the election of Marvin Slosman to its Board of Directors effective December 2, 2025, bringing deep expertise in interventional cardiology that is expected to drive innovation and market expansion in cardiovascular disease treatment.
- Rich Leadership Experience: Slosman, who previously served as CEO of InspireMD and held senior commercial leadership roles at Johnson & Johnson, GE Healthcare, and Baxter International, brings extensive market development and product commercialization experience that will aid BioCardia's strategic growth.
- Gratitude to Former Director: BioCardia expressed appreciation for departing board member Richard Krasno, who provided guidance during key milestones, particularly in the FDA approval of the CardiAMP cell therapy and the Morph DNA product.
- Strategic Company Development: The appointment of Slosman is expected to significantly support BioCardia's clinical value creation and global market expansion, further advancing the company's innovative solutions for treating cardiovascular and pulmonary diseases.
BioCardia Enhances Leadership Team by Appointing Farhan Shahab as Vice President of Quality
New Appointment: BioCardia, Inc. has appointed Farhan Shahab as Vice President of Quality, bringing over 25 years of experience in quality management and regulatory affairs from various companies in the healthcare sector.
Previous Experience: Shahab's prior roles include Vice President of Quality and Regulatory at Welldoc, Senior Director at Intuity Medical, and Director at Moximed, showcasing a strong background in product quality management across multiple medical device categories.
CEO's Statement: Peter Altman, CEO of BioCardia, expressed confidence in Shahab's expertise, stating that his leadership and experience will enhance the company's ability to commercialize investigational products.
Company Overview: BioCardia specializes in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with ongoing development of clinical-stage product candidates and innovative biotherapeutic delivery platforms.
BioCardia, Inc. Reports Smaller Q3 Loss, Surpassing Expectations
Earnings Performance: BioCardia, Inc. reported a loss of $1.48 million for the third quarter, an improvement from a loss of $1.74 million in the same period last year.
Earnings Per Share: The company's earnings per share (EPS) were -$0.24, compared to -$0.61 in the previous year, beating analysts' expectations of -$0.25 per share.
